Dual effect of metformin on growth inhibition and oestradiol production in breast cancer cells

International Journal of Molecular Medicine

Volumn 35, Issue 4, 2015, Pages 1088-1094

  Rice, S ^a   Pellat, L ^c   Ahmetaga, A ^a   Bano, G ^b   Mason, H D ^a   Whitehead, S A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c Bromley College of F and HE   (United Kingdom)

Author keywords

Aromatase; Breast cancer; Metformin; Rapamycin

Indexed keywords

ANDROSTENEDIONE; AROMATASE; ESTRADIOL; ESTRONE; ESTRONE SULFATE; HYDROXYSTEROID DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; METFORMIN; RAPAMYCIN; STERYL SULFATASE; SULFATASE; TESTOSTERONE; ANTINEOPLASTIC AGENT;

ADD ON THERAPY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL DIVISION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MEGADOSE; ENZYME INHIBITION; ESTROGEN SYNTHESIS; GENE EXPRESSION; HUMAN; HUMAN CELL; LOW DRUG DOSE; PRIORITY JOURNAL; PROMOTER REGION; BIOSYNTHESIS; BREAST TUMOR; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; METFORMIN; SIROLIMUS;

EID: 84923684271     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2108     Document Type: Article

References (44)

1. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF and Bost F: Metformin in cancer therapy: A new perspective for an old antidiabetic drug. Mol Cancer Ther 9: 1092-1099, 2010.
2. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305, 2005.
3. Gonzalez-Angulo AM and Meric-Bernstam F: Metformin: A therapeutic opportunity in breast cancer. Clin Cancer Res 16: 1695-1700, 2010.
4. Gallagher EJ and LeRoith D: Diabetes, cancer, and metformin: Connections of metabolism and cell proliferation. Ann NY Acad Sci 1243: 54-68, 2011.
5. Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, La Vecchia C, Mancia G and Corrao G: Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: A meta-analysis. Oncologist 17: 813-822, 2012.
6. Col NF, Ochs L, Springmann V, Aragaki AK and Chlebowski RT: Metformin and breast cancer risk: A meta-analysis and critical literature review. Breast Cancer Res Treat 135: 639-646, 2012.
7. Zhuang Y and Miskimins WK: Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip. J Mol Signal 3: 18-29, 2008.
8. Phoenix KN, Vumbaca F and Claffey KP: Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 113: 101-111, 2009.
9. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE and Thor AD: Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8: 909-915, 2009.
10. Feng YH, Velazquez-Torres G, Gully C, Chen J, Lee MH and Yeung SC: The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J Cell Mol Med 15: 825-836, 2011.
11. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO and de Vries EG: Metformin: Taking away the candy for cancer. Eur J Cancer 46: 2369-2380, 2010.
12. Brown KA, Samarajeewa NU and Simpson ER: Endocrine-related cancers and the role of AMPK. Mol Cell Endocrinol 366: 170-179, 2013.
13. Li J, Kim SG and Blenis J: Rapamycin: One drug, many effects. Cell Metab 19: 373-379, 2014.
14. Vazquez-Martin A, Oliveras-Ferraros C and Menendez JA: The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 8: 88-96, 2009.
15. Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F and Pasqualini JR: Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol 72: 23-27, 2000.
16. Agarwal VR, Bulun SE, Leitch M, Rohrich R and Simpson ER: Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J Clin Endocrinol Metab 81: 3843-3849, 1996.
17. Barnadas A, Estévez LG, Lluch-Hernández A, Rodriguez-Lescure A, Rodriguez-Sanchez C and Sanchez-Rovira P: An overview of letrozole in postmenopausal women with hormone-responsive breast cancer. Adv Ther 28: 1045-1058, 2011.
18. Cook KL, Shajahan AN and Clarke R: Autophagy and endocrine resistance in breast cancer. Expert Rev Anticancer Ther 11: 1283-1294, 2011.
19. Brown KA, Hunger NI, Docanto M and Simpson ER: Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res Treat 123: 591-596, 2010.
20. Samarajeewa NU, Ham S, Yang F, Simpson ER and Brown KA: Promoter-specific effects of metformin on aromatase transcript expression. Steroids 76: 768-771, 2011.
21. Anastasius N, Boston S, Lacey M, Storing N and Whitehead SA: Evidence that low-dose, long-term genistein treatment inhibits oestradiol-stimulated growth in MCF-7 cells by down-regulation of the PI3-kinase/Akt signalling pathway. J Steroid Biochem Mol Biol 116: 50-55, 2009.
22. Rice S, Amon A and Whitehead SA: Ethanolic extracts of black cohosh (Actaea racemosa) inhibit growth and oestradiol synthesis from oestrone sulphate in breast cancer cells. Maturitas 56: 359-367, 2007.
23. Gilling-Smith C, Willis DS, Beard RW and Franks S: Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 79: 1158-1165, 1994.
24. Willis D, Mason H, Gilling-Smith C and Franks S: Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab 81: 302-309, 1996.
25. Rice S, Pellatt L, Ramanathan K, Whitehead SA and Mason HD: Metformin inhibits aromatase via an extracellular signal-regulated kinase-mediated pathway. Endocrinology 150: 4794-4801, 2009.
26. Rice S, Elia A, Jawad Z, Pellatt L and Mason HD: Metformin inhibits follicle-stimulating hormone (FSH) action in human granulosa cells: Relevance to polycystic ovary syndrome. J Clin Endocrinol Metab 98: E1491-E1500, 2013.
27. Utsumi T, Yoshimura N, Takeuchi S, Maruta M, Maeda K and Harada N: Elevated steroid sulfatase expression in breast cancers. J Steroid Biochem Mol Biol 73: 141-145, 2000.
28. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
29. Robert F, Fendri S, Hary L, Lacroix C, Andréjak M and Lalau JD: Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects. Diabetes Metab 29: 279-283, 2003.
30. Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H and Brosen K: The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 21: 837-850, 2011.
31. Jung JW, Park SB, Lee SJ, Seo MS, Trosko JE and Kang KS: Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS One 6: e28068, 2011.
32. Berstein LM, Yue W, Wang JP and Santen RJ: Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells. Breast Cancer Res Treat 128: 109-117, 2011.
33. Ali S and Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2: 101-112, 2002.
34. Seto B: Rapamycin and mTOR: A serendipitous discovery and implications for breast cancer. Clin Transl Med 1: 29, 2012.
35. Beretta L, Gingras AC, Svitkin YV, Hall MN and Sonenberg N: Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 15: 658-664, 1996.
36. Dowling RJ, Zakikhani M, Fantus IG, Pollak M and Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10804-10812, 2007.
37. Zakikhani M, Blouin MJ, Piura E and Pollak MN: Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 123: 271-279, 2010.
38. Lalau JD, Lemaire-Hurtel AS and Lacroix C: Establishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations. Clin Drug Investig 31: 435-438, 2011.
39. Campagnoli C and Berrino F: Venturelli E, Abbà C, Biglia N, Brucato T, Cogliati P, Danese S, Donadio M, Zito G, Pasanisi P: Metformin dereases circulating androgen and oestrogen levels in nondiabetic women with breast cancer. Breast Cancer 13: 433-438, 2013.
40. Mansfield R, Galea R, Brincat M, Hole D and Mason H: Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril 79: 956-962, 2003.
41. Foster PA, Chander SK, Newman SP, et al: A new therapeutic strategy against hormone-dependent breast cancer: The preclinical development of a dual aromatase and sulfatase inhibitor. Clin Cancer Res 14: 6469-6477, 2008.
42. Aka JA, Mazumdar M and Lin SX: Reductive 17beta-hydroxysteroid dehydrogenases in the sulfatase pathway: Critical in the cell proliferation of breast cancer. Mol Cell Endocrinol 301: 183-190, 2009.
43. Osborne CK and Schiff R: Mechansims of endocrine resistance in breast cancer. Annu Rev Med 62: 233-247, 2011.
44. Zhu Z, Jiang W, Thompson MD, McGinley JN and Thompson HJ: Metformin as an energy restriction mimetic agent for breast cancer prevention. J Carcinog 10: 17, 2011.